I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Vitreomacular Traction: Causes, Symptoms, and Treatment
What Is Vitreomacular Traction?
VMT begins with age-related changes to the gel inside your eye called the vitreous. Understanding how this gel normally behaves, and what happens when the separation process is incomplete, helps explain why VMT develops and what it does to your vision.
The vitreous is a clear, jelly-like material that fills most of the inside of the eye. It helps the eye hold its shape and allows light to pass cleanly through to the retina at the back of the eye. The macula is the small but critically important center of the retina, responsible for the sharp, detailed vision we rely on for reading, driving, and recognizing faces.
Normally, the vitreous is loosely attached to the retina and separates cleanly over time. When that separation does not complete properly at the macula, VMT can develop.
As people age, the vitreous gradually shrinks and becomes more watery through a process called syneresis. Eventually, the gel separates from the retina in an event known as a posterior vitreous detachment, or PVD. This is a normal part of aging and causes no problems for most people.
In VMT, this separation does not complete cleanly at the center of the eye. The vitreous pulls away from most of the retina but stays firmly attached to the macula. As the gel continues to contract and pull forward, it creates mechanical stress on the macular tissue. That stress can cause swelling, small fluid-filled pockets called cysts within the retinal layers, and distortion of the macula's normally flat surface.
VMT exists on a spectrum. In its earliest form, the vitreous is attached to the macula but not yet pulling with enough force to cause symptoms or visible structural changes. This is called vitreomacular adhesion. When the attachment begins pulling on and distorting the macular tissue, the condition becomes vitreomacular traction.
If traction continues without intervention, it can lead to complications including macular holes (a full-thickness break in the center of the macula), epiretinal membranes (thin scar-like tissue that forms on the surface of the retina), and cystoid macular edema (swelling caused by fluid buildup within the macular layers). Each of these can cause additional, sometimes significant, vision loss if left unaddressed.
Who Is Most at Risk for VMT?
VMT is primarily an age-related condition, but certain health and eye-specific factors can raise the likelihood of developing it. Understanding these risk factors supports earlier detection and more timely care.
VMT is most common in adults over 60. The condition develops because incomplete vitreous separation becomes more likely as the vitreous undergoes natural aging changes. Research suggests women may be at a somewhat higher risk than men, possibly related to post-menopausal hormonal shifts that can influence how the vitreous behaves over time.
VMT is not considered a common condition in the general population, but it is likely underdiagnosed because the earliest stages often cause no noticeable symptoms and can only be identified through specialized retinal imaging.
Several eye conditions are associated with a higher likelihood of developing VMT. These include:
- Myopia (nearsightedness), which changes the size and internal structure of the eye
- Previous cataract surgery, which can alter the environment inside the eye
- Diabetic retinopathy, a complication of diabetes that affects the small blood vessels of the retina
- Age-related macular degeneration, which weakens the central retina over time
- Retinal vein occlusion, which involves blocked blood flow in a retinal vein
If you have any of these conditions, regular monitoring by a retina specialist is especially important for catching early vitreous and macular changes.
Pilocarpine, a medication sometimes used for presbyopia (the age-related difficulty in focusing on close objects), has been identified as a potential risk factor for VMT. VMT can also develop in both eyes, though it typically begins in one eye at a time.
The size of the area where the vitreous remains attached to the macula plays a meaningful role in how the condition behaves. Smaller, more localized attachments tend to have more favorable outcomes and are more likely to resolve on their own. This is one reason our retinal imaging focuses carefully on measuring the adhesion zone at every follow-up visit.
Recognizing the Symptoms of VMT
Symptoms of VMT can range from no changes at all to meaningful distortion or blurring of central vision. Recognizing what to look for helps you seek care at the right time and know when a symptom warrants an urgent call.
The most common symptom of VMT is metamorphopsia, the medical term for straight lines appearing wavy or bent. You might notice that doorframes, window edges, text on a page, or tile patterns look distorted or curved. This happens because traction on the macula warps its normally flat surface, and your brain interprets that warp as visual distortion.
Decreased central visual acuity, or blurred vision in the center of your field of sight, is also a frequent complaint. Reading, sewing, or recognizing faces across a room can become more difficult. Some people experience micropsia, a condition where objects appear smaller than they actually are.
Some patients with VMT notice a sudden increase in floaters, which are small spots, strings, or cobweb-like shapes that drift across the visual field. Flashes of light, particularly in peripheral vision, can also occur as the vitreous tugs on the retina.
It is important to understand that floaters and flashes are also warning signs of a retinal tear or retinal detachment, both of which are true ocular emergencies. If you experience a sudden onset of new floaters, repeated flashes of light, or a shadow spreading across your vision, do not wait for a routine appointment. Seek evaluation the same day.
In its earliest stages, VMT may cause no noticeable changes in vision. When the vitreous is attached to the macula but not yet pulling with enough force to distort the retinal tissue, the condition is called vitreomacular adhesion. This stage is often found unexpectedly during a routine eye exam or retinal imaging study.
Even without symptoms, a retina specialist will monitor the condition closely over time. Vitreomacular adhesion can progress to symptomatic traction without obvious warning signs, which is why periodic imaging is essential even when you feel your vision is unchanged.
How VMT Is Diagnosed
Diagnosing VMT accurately requires specialized imaging and a thorough retinal examination. The tools we use give us a detailed picture of the vitreous, the macula, and how the two are interacting at any stage of the condition.
Optical coherence tomography, or OCT, is the primary diagnostic tool for VMT. OCT is a painless, non-invasive test that uses light waves to create highly detailed, cross-sectional images of the retina. On OCT, we can see exactly where the vitreous is attached to the macular surface, how much mechanical force it is applying, and what structural changes have already occurred within the retinal layers.
OCT also allows us to measure the width of the adhesion zone precisely. Attachments measuring 1,500 micrometers or less are considered focal and tend to carry a more favorable outlook, including a higher likelihood of spontaneous resolution. Wider adhesions may require earlier or more aggressive intervention.
The Amsler grid is a simple paper or digital tool used to detect and track distortion in central vision. It consists of a grid of straight lines with a small dot at the center. To use it, you cover one eye, hold the grid at normal reading distance, and look steadily at the central dot. If any lines appear wavy, blurry, broken, or missing, this may indicate that the macula is being distorted.
We often ask patients with VMT or vitreomacular adhesion to check the Amsler grid at home as part of self-monitoring between appointments. Any new or worsening changes should be reported to us right away rather than waiting for a scheduled visit.
A dilated eye examination allows us to view the retina and vitreous directly using specialized lenses. This hands-on exam helps identify traction, macular holes, epiretinal membranes, and other changes that imaging alone may not fully characterize.
When additional information is needed, we may recommend fluorescein angiography, a dye-based photographic test that maps blood flow through the retinal vessels. This is particularly useful when conditions such as diabetic retinopathy or retinal vein occlusion are also present or suspected as contributing factors.
Treatment Options for VMT
Not every case of VMT requires immediate intervention. The right approach depends on your symptoms, the size and character of the adhesion, and whether complications have already developed. We take a fully individualized approach to every patient we see.
For many patients, particularly those with smaller adhesions, mild symptoms, and no epiretinal membrane, the first step is careful observation rather than immediate treatment. We use regular OCT imaging and eye exams to track the condition over time and identify the right moment to act if intervention becomes necessary.
VMT resolves on its own in a meaningful portion of eyes, especially when the adhesion is focal and no epiretinal membrane is present. Factors that favor spontaneous resolution include an adhesion measuring under 1,500 micrometers, the absence of an epiretinal membrane, having a natural crystalline lens, and younger age at diagnosis. If spontaneous resolution does not occur and symptoms worsen, we will revisit the treatment options together.
Ocriplasmin, marketed under the brand name Jetrea, is an FDA-approved enzyme injected directly into the vitreous cavity through a procedure called an intravitreal injection. It works by dissolving the protein bonds that hold the vitreous to the macula, encouraging the natural separation process to complete without the need for surgery.
This treatment tends to work best for patients with smaller, focal adhesions and no epiretinal membrane. Not every patient responds, and some whose adhesion does not release may still need surgery. Temporary side effects can include floaters, blurred vision, and mild discomfort, most of which resolve on their own over days to weeks.
Pneumatic vitreolysis is an in-office procedure in which a small gas bubble is injected into the vitreous cavity. The bubble rises and applies gentle pressure against the vitreous attachment at the macula, helping to encourage natural separation without surgery.
This technique is newer and may not be appropriate for all patients. Favorable outcomes have been reported in carefully selected patients, but the approach is not yet as broadly established as injection therapy or vitrectomy. Our team will assess whether it is a suitable option based on the specifics of your imaging and medical history.
Pars plana vitrectomy is a microsurgical procedure in which we remove the vitreous gel from inside the eye through small, precisely placed incisions. By removing the vitreous entirely, we eliminate the source of traction on the macula. The procedure is performed using highly specialized instruments under local anesthesia with sedation.
Vitrectomy is considered the most definitive treatment for VMT and has a high rate of success in releasing traction and improving or stabilizing vision. The removed vitreous is replaced with sterile saline or a gas bubble, and the eye naturally produces fluid to fill the space over time. When a gas bubble is used, patients are asked to maintain a specific head position during recovery and to avoid air travel until the bubble fully dissolves.
Every treatment decision at our practice is individualized. We consider your symptom severity, your current level of vision, the size and location of the adhesion, the presence or absence of complications such as a macular hole or epiretinal membrane, and your overall eye and medical history.
In many cases, we begin with observation and move to intervention only if the condition progresses or your symptoms worsen meaningfully. Our goal is always to protect your vision with the most appropriate approach for your specific situation, not a one-size-fits-all protocol.
What to Expect During and After Treatment
Understanding what each treatment path involves, and what recovery looks like, helps reduce anxiety and allows you to prepare. Here is a practical overview of each stage of the process.
If observation is recommended, you will return to our office for follow-up visits at intervals determined by your individual situation. Each visit typically includes OCT imaging to track any changes in the adhesion or the retinal structure. You may also be asked to perform daily Amsler grid checks between appointments.
If you notice new or worsening distortion, blurring, or any of the urgent symptoms described on this page, contact us promptly rather than waiting for your next scheduled visit. Early communication allows us to adjust your care plan quickly if something changes.
Intravitreal injections are performed in the office under topical anesthetic drops. The procedure itself takes only a few minutes. You may experience mild discomfort, increased floaters, or temporary blurred vision afterward. Most patients are able to return to normal daily activities within a day or two.
Follow-up OCT imaging will be scheduled to assess whether the adhesion has released and how the macula is responding. If the injection achieves a full release, we will continue monitoring to confirm stable recovery. If the adhesion has not released, we will discuss next steps at that visit.
Vitrectomy is performed in an operating room and involves a longer recovery than an office-based injection. You will have post-operative appointments in the days and weeks following surgery to monitor healing and visual progress. Any activity restrictions and head-positioning instructions will be reviewed with you before you go home.
If a gas bubble was placed during the procedure, you will need to avoid flying and high-altitude environments until it fully absorbs, which typically takes several weeks depending on the type of gas used. Vision improvement after vitrectomy is often gradual, with meaningful gains continuing to develop over weeks to months as the macula heals and stabilizes.
The prognosis for VMT depends largely on how early the condition was identified and whether significant structural damage to the macula had already occurred before treatment began. Patients whose traction is addressed before the macula sustains prolonged distortion tend to achieve better visual outcomes.
Some patients may have residual visual distortion even after traction has been successfully released. This is more common when the macular tissue was stretched or damaged over an extended period. Ongoing follow-up with our team helps us monitor for any recurrence and detect new changes in the other eye as early as possible.
Caring for Your Vision at Home
Living with VMT, or recovering from treatment, involves practical habits that can help you monitor your vision, adapt to any changes, and stay connected to your care team between visits.
Checking the Amsler grid once a day is one of the most useful things you can do to stay informed about your central vision between office visits. Hold the grid at a comfortable reading distance in good light, cover one eye at a time, and focus steadily on the center dot. Note whether any lines appear wavy, bent, blurry, or missing.
Keeping a simple daily log makes it easier to detect subtle changes over time. If you notice new distortion or a change from what you observed the day before, contact us promptly. Small changes can be clinically meaningful in someone with VMT or vitreomacular adhesion.
If your central vision has been affected, several adjustments can make daily tasks more manageable. Good lighting helps significantly with reading and close-up work. Magnifying devices, large-print materials, and screen-reading software or display settings can all reduce strain while your vision is changing or recovering after treatment.
Low vision rehabilitation services, often available through hospitals and community health organizations, provide structured support to help patients adapt to functional vision changes. These programs offer tools and training for everyday activities such as reading, preparing meals, managing finances, and using technology. They complement your ongoing medical care but are not a substitute for it.
Consistent follow-up is one of the most important things you can do to manage VMT safely and effectively. Even when vision feels stable or you believe things are improving, retinal conditions can change without obvious warning. Regular OCT scans and examinations allow us to detect new developments before they become more difficult to treat.
If you need to reschedule an appointment, please let us know as soon as possible so we can find the earliest available time. Missing follow-up visits is one of the most common ways that treatable changes go undetected in retinal disease.
When to Seek Immediate Care
While VMT is often a gradually evolving condition, some vision changes require urgent or emergency evaluation. Knowing when to act quickly can protect your vision in ways that waiting cannot.
If you are over 60, have any of the risk factors described on this page, or have been told by your eye doctor that you have vitreous changes, a thorough dilated eye exam at least once a year is a reasonable starting point. Your optometrist or general ophthalmologist can screen for vitreous and macular changes and refer you to a retina specialist if something is found. Early detection through routine care gives us the widest range of options for managing VMT effectively.
Some symptoms cannot wait for a scheduled appointment. Contact us immediately or go to the nearest emergency room if you experience any of the following:
- A sudden large increase in floaters, especially if they appear new or look different from ones you have had before
- New or repeating flashes of light in your peripheral vision
- A shadow, curtain, or dark area spreading across any part of your visual field
- Sudden loss of vision in one eye
- A rapid or dramatic worsening of visual distortion
These symptoms can indicate a retinal tear, retinal detachment, or rapid progression of VMT. These are true ocular emergencies. Prompt evaluation and treatment can be the difference between preserving useful vision and permanent vision loss.
Frequently Asked Questions
Here are answers to questions we commonly hear from patients learning about VMT for the first time. Each answer is meant to add practical guidance that goes a step beyond what is covered above.
Yes, VMT can resolve spontaneously when the vitreous naturally completes its separation from the macula. This is most likely when the adhesion is smaller and no epiretinal membrane is present. Because spontaneous resolution can take many months to over a year, observation is a reasonable first step for appropriately selected patients. However, if vision deteriorates or complications develop during the monitoring period, we will adjust the plan rather than continuing to wait indefinitely.
VMT and macular holes are closely related but distinct diagnoses. VMT refers to the vitreous pulling on and distorting the macula without creating a break in the tissue. A macular hole forms when that pulling force is severe enough or prolonged enough to cause a full-thickness break in the center of the macular tissue. Not all cases of VMT progress to a macular hole, and macular holes can also develop through other mechanisms. Treating VMT before it causes a hole reduces the risk, though it does not eliminate it entirely.
Ocriplasmin works best for a specific subset of patients, particularly those with smaller focal adhesions and no epiretinal membrane. When those conditions are met, the medication can successfully release the vitreous attachment without surgery. Success rates are lower for patients with wider adhesions or a coexisting epiretinal membrane. For patients who do not respond to the injection, vitrectomy surgery remains an effective and well-established option. We will review your imaging with you to discuss which approach gives you the best chance of a favorable outcome.
Vitrectomy for VMT is typically a brief outpatient procedure, but recovery varies by patient. If a gas bubble is placed during surgery, you will need to follow specific head-positioning instructions, avoid flying, and stay away from high-altitude locations until the bubble fully absorbs, which typically takes several weeks. Vision improvement after surgery tends to be gradual and may continue for two to three months or longer as the macula heals and the eye adjusts.
VMT can develop in both eyes, though it most commonly begins in one eye at a time. Because the age-related vitreous changes that lead to VMT occur in both eyes, the second eye is always worth monitoring closely. During your follow-up visits with us, we examine and image both eyes to detect any early changes in the fellow eye so that we can respond quickly if something develops.
Expert Retina Care at New England Retina Associates
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons have extensive experience diagnosing and treating vitreomacular traction at every stage, from early monitoring through complex surgical care. We welcome self-referred patients, referred patients, and those who need urgent evaluation throughout Connecticut. If you have recently been told you may have VMT or your vision has changed in ways that concern you, we are here to help you understand your options and move forward with confidence in your care.
30 Years of Care & Commitment
